Hospital
Humboldt General Hospital
Humboldt General Hospital was paid $4.44M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoHUMBOLDT GENERAL HOSPITAL
WINNEMUCCA, NV 89445
WINNEMUCCA, NV 89445
33aNPI1750498010assigned 08/24/2006
33bProvider typeCritical Access Hospital
28Total paid$4.44M
24GClaims221,450
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Nevada
Rank by total paid#1 of 9
Median peer was paid$955K
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,832 | $254K | |
| 2019 | 30,814 | $337K | |
| 2020 | 27,793 | $251K | |
| 2021 | 31,256 | $332K | |
| 2022 | 36,079 | $403K | |
| 2023 | 41,777 | $424K | |
| 2024incomplete | 31,899 | $2.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 8,842 | 7,279 | $957K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 6,624 | 5,061 | $810K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 886 | 565 | $513K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 4,113 | 2,878 | $499K |
| 70450 | Computed tomography, head or brain; without contrast material | 7.2% | 1,204 | 880 | $322K |
| G0378 | Hospital observation service, per hour | 5.0% | 2,044 | 988 | $221K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 2,233 | 1,963 | $163K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.5% | 1,745 | 1,387 | $110K |
| 80053 | Comprehensive metabolic panel | 2.4% | 16,638 | 11,678 | $107K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 1,503 | 1,350 | $53K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 339 | 300 | $52K |
| 80050 | General health panel | 1.0% | 420 | 403 | $46K |
150 more codes
| 86703 | <1% | 1,139 | $43K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,002 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,868 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,763 | $39K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 133 | $35K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 384 | $29K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,096 | $28K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,939 | $23K |
| 80061 | Lipid panel | <1% | 4,994 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,172 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,881 | $20K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 202 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,636 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,452 | $17K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 342 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,799 | $16K |
| 84702 | <1% | 1,866 | $15K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 591 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,687 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 761 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,161 | $7K |
| 83880 | <1% | 607 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,872 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 396 | $6K |
| 86850 | <1% | 1,321 | $5K | |
| 73630 | <1% | 166 | $5K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,689 | $4K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 101 | $4K |
| 59025 | Fetal non-stress test | <1% | 146 | $4K |
| 73030 | <1% | 83 | $4K | |
| 81000 | <1% | 5,231 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,037 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 221 | $3K |
| 81002 | <1% | 657 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 122 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 328 | $3K |
| 83540 | <1% | 347 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,273 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,034 | $2K |
| 80076 | <1% | 184 | $2K | |
| 76801 | <1% | 28 | $2K | |
| 87081 | <1% | 1,286 | $2K | |
| 88174 | <1% | 70 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,453 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,447 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,133 | $2K |
| 73564 | <1% | 87 | $1K | |
| 83690 | <1% | 2,720 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 55 | $1K |
| 82607 | <1% | 499 | $1K | |
| 73130 | <1% | 32 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 65 | $1K |
| 83735 | <1% | 1,335 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 623 | $1K |
| 87077 | <1% | 928 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 39 | $829.40 |
| 82728 | <1% | 61 | $777.48 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 936 | $769.59 |
| 73110 | <1% | 15 | $735.85 | |
| 82652 | <1% | 17 | $555.46 | |
| 84439 | <1% | 2,079 | $514.03 | |
| 82570 | <1% | 1,478 | $510.45 | |
| 80069 | <1% | 115 | $456.41 | |
| 85027 | <1% | 1,294 | $400.91 | |
| 85610 | <1% | 1,756 | $394.29 | |
| 73610 | <1% | 18 | $355.72 | |
| 82043 | <1% | 1,133 | $354.47 | |
| 82784 | <1% | 114 | $342.71 | |
| 86803 | <1% | 367 | $329.58 | |
| 84703 | <1% | 1,036 | $327.97 | |
| 84484 | <1% | 3,268 | $256.61 | |
| 87340 | <1% | 713 | $246.14 | |
| 81001 | <1% | 2,184 | $210.56 | |
| 86901 | <1% | 1,043 | $189.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 833 | $182.97 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 48 | $173.54 |
| 82951 | <1% | 73 | $126.81 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,937 | $126.53 |
| 88142 | <1% | 86 | $110.56 | |
| 87430 | <1% | 489 | $88.21 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,287 | $72.15 |
| 36416 | <1% | 70 | $61.41 | |
| 87070 | <1% | 12 | $58.80 | |
| 86317 | <1% | 206 | $49.10 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,060 | $48.61 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 28 | $47.86 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 837 | $46.78 |
| 94664 | <1% | 80 | $37.08 | |
| 82950 | <1% | 29 | $33.93 | |
| 83605 | <1% | 368 | $32.97 | |
| 87210 | <1% | 159 | $32.01 | |
| 86593 | <1% | 672 | $30.73 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 904 | $27.92 |
| 85730 | <1% | 324 | $27.07 | |
| 86900 | <1% | 1,176 | $22.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 205 | $20.77 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,881 | $20.09 |
| 85379 | <1% | 107 | $18.99 | |
| 82948 | <1% | 394 | $18.16 | |
| 86140 | <1% | 835 | $14.12 | |
| 87040 | <1% | 204 | $14.10 | |
| 86592 | <1% | 1,010 | $11.64 | |
| 87181 | <1% | 1,103 | $11.50 | |
| 85651 | <1% | 625 | $11.04 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,748 | $10.10 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,169 | $7.09 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 371 | $3.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 98 | $0.49 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 626 | $0.14 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 47 | $0.02 |
| 84550 | 0% | 85 | $0.00 | |
| G9656 | Patient transferred directly from anesthetizing location to pacu or other non-icu location | 0% | 507 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 48 | $0.00 |
| A0425 | Ground mileage, per statute mile | 0% | 216 | $0.00 |
| 84481 | 0% | 48 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 141 | $0.00 |
| 84100 | 0% | 45 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 38 | $0.00 |
| 84207 | 0% | 15 | $0.00 | |
| 99001 | 0% | 40 | $0.00 | |
| 84425 | 0% | 13 | $0.00 | |
| 84295 | 0% | 13 | $0.00 | |
| 86708 | 0% | 14 | $0.00 | |
| 80179 | 0% | 15 | $0.00 | |
| 80143 | 0% | 15 | $0.00 | |
| 82746 | 0% | 175 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 1,121 | $0.00 |
| 94761 | 0% | 653 | $0.00 | |
| 84436 | 0% | 64 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 353 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 312 | $0.00 |
| 86706 | 0% | 105 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 0% | 590 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 207 | $0.00 |
| 83550 | 0% | 170 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 32 | $0.00 |
| 86762 | 0% | 12 | $0.00 | |
| 99002 | 0% | 88 | $0.00 | |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | 0% | 48 | $0.00 |
| 82550 | 0% | 52 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 159 | $0.00 |
| J3490 | Unclassified drugs | 0% | 92 | $0.00 |
| 84479 | 0% | 29 | $0.00 | |
| 96376 | 0% | 32 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 19 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 21 | $0.00 |
| 80329 | 0% | 17 | $0.00 | |
| 81015 | 0% | 17 | $0.00 | |
| 86704 | 0% | 14 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUNCKHORST, ROBYN (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Humboldt General Hospital | Winnemucca, NV | $6.26M |
| Humboldt General Hospital | Winnemucca, NV | $576K |
| Humboldt General Hospital | Winnemucca, NV | $30K |
| Humboldt General Hospital | Winnemucca, NV | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.